ESTRO meets Asia 2024 - Abstract Book

S260

Interdisciplinary – Sarcoma/skin cancer/malignant carcinoma

ESTRO meets Asia 2024

In situ vaccination with“FOLactis", along with SBRT was tolerable and induced anti-tumor immunity, which would also trigger systemic response when synergized with PD-1 mAb. This in situ vaccination is probably a promising option for advanced solid tumors with sarcomas as a preferred option.

Keywords: SBRT, intratumoral injection, immunotherapy

References:

[1] Saxena M, van der Burg S H, Melief C J M, et al. Therapeutic cancer vaccines[J]. Nature Reviews Cancer, 2021,21(6):360-378.

[2] Hammerich L, Binder A, Brody JD. In situ vaccination: Cancer immunotherapy both personalized and off-the shelf[J]. MolOncol, 2015, 9(10): 1966-1981.

[3] Jarosz-Biej M, Smolarczyk R, Cichon T, et al. Brachytherapy in a Single Dose of 10Gy as an “in situ” Vaccination[J]. Int J Mol Sci, 2020, 21(13): 4585.

[4] Zhu J, Ke Y, Liu Q, et al. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination based cancer immunotherapy[J]. Nat Commun, 2022,13(1):7466.